Axsome Therapeutics, Inc
AXSMAxsome Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative medicines for the treatment of central nervous system (CNS) disorders, including depression, migraine, and Parkinson's disease. The company aims to address unmet medical needs through novel proprietary compounds and formulations.
Company News
The article highlights two biotechnology companies, Therapeutics and Exelixis, as promising investment opportunities for 2026 due to their innovative drug pipelines and potential for significant market growth.
Axsome Therapeutics will participate in two investor conferences in December 2025, including the Piper Sandler Healthcare Conference and BofA Securities CNS Therapeutics Virtual Conference, presenting their latest developments in central nervous system treatments.
Teva Pharmaceutical and Biolojic Design announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP and IL-13, which can potentially improve outcomes for patients with conditions such as atopic dermatitis and asthma.
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Biotech stocks have been heavily impacted by rising interest rates and FTC challenges. Find out my investment strategy while selecting biotech names.
